Lead Product(s) : Endostatin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition
Denovo Biopharma Acquires a Novel Late-Stage Oncology Drug and Expands into Protein Therapeutics
Details : DB108 is a recombinant protein drug that inhibits tumor growth and metastasis by inhibiting angiogenesis. Denovo gains global rights (except China) to develop, manufacture and commercialize endostatin from Jiangsu Wuzhong Pharmaceutical Group Corporation...
Product Name : DB108
Product Type : Protein
Upfront Cash : Undisclosed
October 12, 2020
Lead Product(s) : Endostatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition